# Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular disease

> **NIH NIH P20** · UNIVERSITY OF KENTUCKY · 2020 · $299,072

## Abstract

PROJECT SUMMARY / ABSTRACT – PROJECT 4
The identification of autoantigens in atherosclerotic plaques has prompted investigation of the antibody-mediated
pathogenesis of cardiovascular disease (CVD). Detailed characterization of the antigen, epitope specificity,
antibody subclass and receptor engagement will enhance the understanding of CVD and guide therapeutic
development. One target of IgG antibody induction in patients is apolipoprotein A-I (ApoA-I), the major protein of
high density lipoprotein (HDL). Although anti-ApoA-I antibodies have been identified in mice and human subjects,
the role of these antibodies have not been elucidated. Furthermore, the immunologic impact of antibodies bound
to ApoA-I in an immune complex (ApoA-I/IgG ICs) is unclear. The long-term goal is to develop novel peptide
and antibody therapeutics based on mechanistic insight from mice, to reduce the burden of CVD in patients. To
achieve this goal, the overall objectives of this proposal build from our observations in human subjects to
characterize the molecular components of the anti-ApoA-I antibody response in mice and correlate their
characteristics with cellular interactions, functional outcomes and atherosclerosis progression. The hypothesis
is that anti-ApoA-I antibodies exhibit both pro- and anti-inflammatory effects depending on the antibody
characteristics (i.e. subclass, epitope specificity, Fc receptor interaction) leading to exacerbation or suppression
of atherosclerosis. The rationale for this proposed research is that understanding one component of the immune
response associated with CVD will promote improved patient outcomes through novel therapeutic strategies.
Encouraged by strong preliminary data, this hypothesis will be tested through two specific aims: 1) Elucidate
the molecular components and functional implications of antibodies targeting peptide epitopes derived from
ApoA-I; and 2) Determine if ApoA-I/IgG ICs mediate an anti-inflammatory phenotype by engaging with the
inhibitory Fc receptor using in vitro assays and in vivo studies in atherosusceptible mouse models. In the first
aim, a structure immunogenicity relationship will be generated by correlating in silico modeling, biophysical
characterization and immunogenicity studies of known peptide epitopes derived from ApoA-I. These data will be
correlated with antibody profiles and subclass composition of the antibody response toward ApoA-I. In the
second aim, the mechanistic impact of anti-ApoA-I antibodies will be determined by characterizing cell
polarization in the presence of specific anti-ApoA-I profiles and inducing antibody profiles in atherosusceptible
mice lacking Fc receptors. The innovation and significance of the proposed work is driven by the novel
immunomodulation strategies that will improve our understanding of antibody-mediated immune responses,
which will guide continued efforts to develop novel immunotherapies through coordination with the CPRI COBRE,
to decrease the burden of ...

## Key facts

- **NIH application ID:** 9854241
- **Project number:** 1P20GM130456-01A1
- **Recipient organization:** UNIVERSITY OF KENTUCKY
- **Principal Investigator:** Vincent Joseph Venditto
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $299,072
- **Award type:** 1
- **Project period:** 2020-03-01 → 2025-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9854241

## Citation

> US National Institutes of Health, RePORTER application 9854241, Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular disease (1P20GM130456-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9854241. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*